nodes	percent_of_prediction	percent_of_DWPC	metapath
Acamprosate—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Acamprosate—Asthenia—Teniposide—lymphatic system cancer	0.0019	0.0019	CcSEcCtD
Acamprosate—Melaena—Methotrexate—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Acamprosate—Malaise—Bleomycin—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Acamprosate—Pruritus—Teniposide—lymphatic system cancer	0.00187	0.00187	CcSEcCtD
Acamprosate—Leukopenia—Bleomycin—lymphatic system cancer	0.00187	0.00187	CcSEcCtD
Acamprosate—Alopecia—Carmustine—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Acamprosate—Body temperature increased—Fludarabine—lymphatic system cancer	0.00184	0.00184	CcSEcCtD
Acamprosate—Mental disorder—Carmustine—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Acamprosate—Vaginal infection—Methotrexate—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Acamprosate—Malnutrition—Carmustine—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Acamprosate—Cough—Bleomycin—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Acamprosate—Diarrhoea—Teniposide—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Acamprosate—Chest pain—Bleomycin—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Acamprosate—Myalgia—Bleomycin—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Acamprosate—Alopecia—Vincristine—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Acamprosate—Back pain—Carmustine—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Acamprosate—Discomfort—Bleomycin—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Acamprosate—Mental disorder—Vincristine—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Acamprosate—Chills—Mitoxantrone—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Acamprosate—Mouth ulceration—Methotrexate—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Acamprosate—Ecchymosis—Methotrexate—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Acamprosate—Urine output increased—Methotrexate—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Acamprosate—Alopecia—Mitoxantrone—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Acamprosate—Confusional state—Bleomycin—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Acamprosate—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Acamprosate—Tremor—Carmustine—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Acamprosate—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Acamprosate—Infection—Bleomycin—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Acamprosate—Anaemia—Carmustine—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Acamprosate—Back pain—Vincristine—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Acamprosate—Vomiting—Teniposide—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Acamprosate—Agitation—Carmustine—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Acamprosate—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Acamprosate—Asthenia—Fludarabine—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Acamprosate—Rash—Teniposide—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Acamprosate—Dermatitis—Teniposide—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Acamprosate—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Acamprosate—Headache—Teniposide—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Acamprosate—Pruritus—Fludarabine—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Acamprosate—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Acamprosate—Back pain—Mitoxantrone—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Acamprosate—Leukopenia—Carmustine—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Acamprosate—Anorexia—Bleomycin—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Acamprosate—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Acamprosate—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Acamprosate—Anaemia—Vincristine—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Acamprosate—Agitation—Vincristine—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Acamprosate—Polyuria—Methotrexate—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Acamprosate—Hypotension—Bleomycin—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Acamprosate—Diarrhoea—Fludarabine—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Acamprosate—Convulsion—Carmustine—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Acamprosate—Hypertension—Carmustine—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Acamprosate—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Acamprosate—Nausea—Teniposide—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Acamprosate—Anaemia—Mitoxantrone—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Acamprosate—Vertigo—Vincristine—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Acamprosate—Leukopenia—Vincristine—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Acamprosate—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Acamprosate—Chest pain—Carmustine—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Acamprosate—Myalgia—Carmustine—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Acamprosate—Anxiety—Carmustine—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Acamprosate—Paraesthesia—Bleomycin—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Acamprosate—Malaise—Mitoxantrone—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Acamprosate—Dyspnoea—Bleomycin—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Acamprosate—Renal failure acute—Methotrexate—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Acamprosate—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Acamprosate—Convulsion—Vincristine—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Acamprosate—Hypertension—Vincristine—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Acamprosate—Confusional state—Carmustine—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Acamprosate—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Acamprosate—Decreased appetite—Bleomycin—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Acamprosate—Myalgia—Vincristine—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Acamprosate—Cough—Mitoxantrone—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Acamprosate—Infection—Carmustine—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Acamprosate—Vomiting—Fludarabine—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Acamprosate—Convulsion—Mitoxantrone—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Acamprosate—Rash—Fludarabine—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Acamprosate—Dermatitis—Fludarabine—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Acamprosate—Hypertension—Mitoxantrone—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Acamprosate—Pain—Bleomycin—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Acamprosate—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Acamprosate—Headache—Fludarabine—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Acamprosate—Tachycardia—Carmustine—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Acamprosate—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Acamprosate—Chest pain—Mitoxantrone—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Acamprosate—Myalgia—Mitoxantrone—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Acamprosate—Anxiety—Mitoxantrone—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Acamprosate—Discomfort—Mitoxantrone—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Acamprosate—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Acamprosate—Anorexia—Carmustine—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Acamprosate—Infection—Vincristine—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Acamprosate—Feeling abnormal—Bleomycin—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Acamprosate—Confusional state—Mitoxantrone—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Acamprosate—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Acamprosate—Hypotension—Carmustine—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Acamprosate—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Acamprosate—Nausea—Fludarabine—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Acamprosate—Infection—Mitoxantrone—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Acamprosate—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Acamprosate—Shock—Mitoxantrone—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Acamprosate—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Acamprosate—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Acamprosate—Urticaria—Bleomycin—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Acamprosate—Anorexia—Vincristine—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Acamprosate—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Acamprosate—Body temperature increased—Bleomycin—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Acamprosate—Insomnia—Carmustine—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Acamprosate—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Acamprosate—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Acamprosate—Paraesthesia—Carmustine—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Acamprosate—Hypotension—Vincristine—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Acamprosate—Dyspnoea—Carmustine—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Acamprosate—Somnolence—Carmustine—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Acamprosate—Anorexia—Mitoxantrone—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Acamprosate—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Acamprosate—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Acamprosate—Decreased appetite—Carmustine—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Acamprosate—Hypotension—Mitoxantrone—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Acamprosate—Insomnia—Vincristine—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Acamprosate—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Acamprosate—Paraesthesia—Vincristine—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Acamprosate—Constipation—Carmustine—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Acamprosate—Pain—Carmustine—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Acamprosate—Breast disorder—Methotrexate—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Acamprosate—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Acamprosate—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Acamprosate—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Acamprosate—Decreased appetite—Vincristine—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Acamprosate—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Acamprosate—Somnolence—Mitoxantrone—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Acamprosate—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Acamprosate—Feeling abnormal—Carmustine—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Acamprosate—Asthenia—Bleomycin—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Acamprosate—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Acamprosate—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Acamprosate—Constipation—Vincristine—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Acamprosate—Pain—Vincristine—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Acamprosate—Asthma—Methotrexate—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Acamprosate—Pruritus—Bleomycin—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Acamprosate—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Acamprosate—Eosinophilia—Methotrexate—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Acamprosate—Pancreatitis—Methotrexate—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Acamprosate—Pain—Mitoxantrone—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Acamprosate—Constipation—Mitoxantrone—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Acamprosate—Abdominal pain—Carmustine—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Acamprosate—Body temperature increased—Carmustine—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Acamprosate—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Acamprosate—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Acamprosate—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Acamprosate—Body temperature increased—Vincristine—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Acamprosate—Abdominal pain—Vincristine—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Acamprosate—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Acamprosate—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Acamprosate—Urticaria—Mitoxantrone—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Acamprosate—Hypersensitivity—Carmustine—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Acamprosate—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Acamprosate—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Acamprosate—Pneumonia—Methotrexate—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Acamprosate—Vomiting—Bleomycin—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Acamprosate—Depression—Methotrexate—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Acamprosate—Rash—Bleomycin—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Acamprosate—Dermatitis—Bleomycin—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Acamprosate—Asthenia—Carmustine—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Acamprosate—Stomatitis—Methotrexate—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Acamprosate—Hypersensitivity—Vincristine—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Acamprosate—Sweating—Methotrexate—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Acamprosate—Haematuria—Methotrexate—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Acamprosate—Epistaxis—Methotrexate—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Acamprosate—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Acamprosate—Asthenia—Vincristine—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Acamprosate—Diarrhoea—Carmustine—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Acamprosate—Nausea—Bleomycin—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Acamprosate—Asthenia—Mitoxantrone—lymphatic system cancer	0.000991	0.000991	CcSEcCtD
Acamprosate—Dizziness—Carmustine—lymphatic system cancer	0.000982	0.000982	CcSEcCtD
Acamprosate—Haemoglobin—Methotrexate—lymphatic system cancer	0.000974	0.000974	CcSEcCtD
Acamprosate—Diarrhoea—Vincristine—lymphatic system cancer	0.00097	0.00097	CcSEcCtD
Acamprosate—Haemorrhage—Methotrexate—lymphatic system cancer	0.000969	0.000969	CcSEcCtD
Acamprosate—Hepatitis—Methotrexate—lymphatic system cancer	0.000969	0.000969	CcSEcCtD
Acamprosate—Pharyngitis—Methotrexate—lymphatic system cancer	0.000961	0.000961	CcSEcCtD
Acamprosate—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000945	0.000945	CcSEcCtD
Acamprosate—Vomiting—Carmustine—lymphatic system cancer	0.000945	0.000945	CcSEcCtD
Acamprosate—Dizziness—Vincristine—lymphatic system cancer	0.000938	0.000938	CcSEcCtD
Acamprosate—Rash—Carmustine—lymphatic system cancer	0.000937	0.000937	CcSEcCtD
Acamprosate—Dermatitis—Carmustine—lymphatic system cancer	0.000936	0.000936	CcSEcCtD
Acamprosate—Visual impairment—Methotrexate—lymphatic system cancer	0.000933	0.000933	CcSEcCtD
Acamprosate—Headache—Carmustine—lymphatic system cancer	0.000931	0.000931	CcSEcCtD
Acamprosate—Tinnitus—Methotrexate—lymphatic system cancer	0.000903	0.000903	CcSEcCtD
Acamprosate—Vomiting—Vincristine—lymphatic system cancer	0.000902	0.000902	CcSEcCtD
Acamprosate—Rash—Vincristine—lymphatic system cancer	0.000894	0.000894	CcSEcCtD
Acamprosate—Dermatitis—Vincristine—lymphatic system cancer	0.000893	0.000893	CcSEcCtD
Acamprosate—Headache—Vincristine—lymphatic system cancer	0.000888	0.000888	CcSEcCtD
Acamprosate—Nausea—Carmustine—lymphatic system cancer	0.000882	0.000882	CcSEcCtD
Acamprosate—Vomiting—Mitoxantrone—lymphatic system cancer	0.000878	0.000878	CcSEcCtD
Acamprosate—Immune system disorder—Methotrexate—lymphatic system cancer	0.000875	0.000875	CcSEcCtD
Acamprosate—Rash—Mitoxantrone—lymphatic system cancer	0.000871	0.000871	CcSEcCtD
Acamprosate—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00087	0.00087	CcSEcCtD
Acamprosate—Chills—Methotrexate—lymphatic system cancer	0.000869	0.000869	CcSEcCtD
Acamprosate—Headache—Mitoxantrone—lymphatic system cancer	0.000865	0.000865	CcSEcCtD
Acamprosate—Alopecia—Methotrexate—lymphatic system cancer	0.000856	0.000856	CcSEcCtD
Acamprosate—Mental disorder—Methotrexate—lymphatic system cancer	0.000849	0.000849	CcSEcCtD
Acamprosate—Malnutrition—Methotrexate—lymphatic system cancer	0.000843	0.000843	CcSEcCtD
Acamprosate—Nausea—Vincristine—lymphatic system cancer	0.000842	0.000842	CcSEcCtD
Acamprosate—Dysgeusia—Methotrexate—lymphatic system cancer	0.000826	0.000826	CcSEcCtD
Acamprosate—Nausea—Mitoxantrone—lymphatic system cancer	0.00082	0.00082	CcSEcCtD
Acamprosate—Back pain—Methotrexate—lymphatic system cancer	0.000816	0.000816	CcSEcCtD
Acamprosate—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000782	0.000782	CcSEcCtD
Acamprosate—Anaemia—Methotrexate—lymphatic system cancer	0.000779	0.000779	CcSEcCtD
Acamprosate—Malaise—Methotrexate—lymphatic system cancer	0.00076	0.00076	CcSEcCtD
Acamprosate—Vertigo—Methotrexate—lymphatic system cancer	0.000758	0.000758	CcSEcCtD
Acamprosate—Leukopenia—Methotrexate—lymphatic system cancer	0.000755	0.000755	CcSEcCtD
Acamprosate—Cough—Methotrexate—lymphatic system cancer	0.000736	0.000736	CcSEcCtD
Acamprosate—Convulsion—Methotrexate—lymphatic system cancer	0.000731	0.000731	CcSEcCtD
Acamprosate—Arthralgia—Methotrexate—lymphatic system cancer	0.000718	0.000718	CcSEcCtD
Acamprosate—Chest pain—Methotrexate—lymphatic system cancer	0.000718	0.000718	CcSEcCtD
Acamprosate—Myalgia—Methotrexate—lymphatic system cancer	0.000718	0.000718	CcSEcCtD
Acamprosate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000713	0.000713	CcSEcCtD
Acamprosate—Discomfort—Methotrexate—lymphatic system cancer	0.000709	0.000709	CcSEcCtD
Acamprosate—Confusional state—Methotrexate—lymphatic system cancer	0.000694	0.000694	CcSEcCtD
Acamprosate—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000688	0.000688	CcSEcCtD
Acamprosate—Infection—Methotrexate—lymphatic system cancer	0.000684	0.000684	CcSEcCtD
Acamprosate—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000674	0.000674	CcSEcCtD
Acamprosate—Skin disorder—Methotrexate—lymphatic system cancer	0.000668	0.000668	CcSEcCtD
Acamprosate—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000665	0.000665	CcSEcCtD
Acamprosate—Anorexia—Methotrexate—lymphatic system cancer	0.000656	0.000656	CcSEcCtD
Acamprosate—Hypotension—Methotrexate—lymphatic system cancer	0.000643	0.000643	CcSEcCtD
Acamprosate—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000627	0.000627	CcSEcCtD
Acamprosate—Insomnia—Methotrexate—lymphatic system cancer	0.000622	0.000622	CcSEcCtD
Acamprosate—Paraesthesia—Methotrexate—lymphatic system cancer	0.000618	0.000618	CcSEcCtD
Acamprosate—Dyspnoea—Methotrexate—lymphatic system cancer	0.000614	0.000614	CcSEcCtD
Acamprosate—Somnolence—Methotrexate—lymphatic system cancer	0.000612	0.000612	CcSEcCtD
Acamprosate—Dyspepsia—Methotrexate—lymphatic system cancer	0.000606	0.000606	CcSEcCtD
Acamprosate—Decreased appetite—Methotrexate—lymphatic system cancer	0.000598	0.000598	CcSEcCtD
Acamprosate—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000594	0.000594	CcSEcCtD
Acamprosate—Pain—Methotrexate—lymphatic system cancer	0.000588	0.000588	CcSEcCtD
Acamprosate—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000567	0.000567	CcSEcCtD
Acamprosate—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000563	0.000563	CcSEcCtD
Acamprosate—Urticaria—Methotrexate—lymphatic system cancer	0.000547	0.000547	CcSEcCtD
Acamprosate—Body temperature increased—Methotrexate—lymphatic system cancer	0.000544	0.000544	CcSEcCtD
Acamprosate—Abdominal pain—Methotrexate—lymphatic system cancer	0.000544	0.000544	CcSEcCtD
Acamprosate—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000507	0.000507	CcSEcCtD
Acamprosate—Asthenia—Methotrexate—lymphatic system cancer	0.000494	0.000494	CcSEcCtD
Acamprosate—Pruritus—Methotrexate—lymphatic system cancer	0.000487	0.000487	CcSEcCtD
Acamprosate—Diarrhoea—Methotrexate—lymphatic system cancer	0.000471	0.000471	CcSEcCtD
Acamprosate—Dizziness—Methotrexate—lymphatic system cancer	0.000455	0.000455	CcSEcCtD
Acamprosate—Vomiting—Methotrexate—lymphatic system cancer	0.000438	0.000438	CcSEcCtD
Acamprosate—Rash—Methotrexate—lymphatic system cancer	0.000434	0.000434	CcSEcCtD
Acamprosate—Dermatitis—Methotrexate—lymphatic system cancer	0.000433	0.000433	CcSEcCtD
Acamprosate—Headache—Methotrexate—lymphatic system cancer	0.000431	0.000431	CcSEcCtD
Acamprosate—Nausea—Methotrexate—lymphatic system cancer	0.000409	0.000409	CcSEcCtD
